Dr. Adrien Holzgreve, a visiting assistant professor of the Theranostics Clinical Research Program in the Ahmanson Translational Theranostics Division at UCLA, has been recognized as a rising star in nuclear medicine and molecular imaging through the Society of Nuclear Medicine and Molecular Imaging’s Ones to Watch program.
This national recognition places Holzgreve among a select group of emerging leaders in nuclear medicine and molecular imaging who are poised to shape the future of precision medicine.
Under the direction of Dr. Jeremie Calais, director of the Ahmanson Translational Theranostics Division’s clinical research program and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, Holzgreve is studying how advanced imaging technologies like PSMA-PET and treatments like PSMA radioligand therapy can improve the management of patients with prostate cancer.
Most recently, Holzgreve, Calais and colleagues found that nearly half of high-risk prostate cancer patients previously believed to have nonmetastatic disease in the hormone-sensitive stage actually had metastatic spread that was missed by conventional imaging. These findings have important implications for clinical trial design and treatment planning, reinforcing the need to incorporate molecular imaging into standard care to more accurately guide personalized therapies.
“It’s an honor to be recognized by SNMMI,” Holzgreve said. “This award reflects the strength of our team at UCLA and our shared commitment to using advanced theranostic concepts to push the boundaries of how we understand, diagnose and treat cancer.”
